Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Galcanezumab has demonstrated a clear clinical advantage over placebo in reducing the number of monthly migraine days for both episodic and chronic migraine, with significant improvements noted in the trials. The evidence indicates that more patients experienced a reduction of at least 50% in monthly migraine days for episodic migraine and at least 30% for chronic migraine, which supports its effectiveness as a treatment option after failure of prior therapies. This strengthens the market access risk assessment and overall reimbursement probability.
Cost effectiveness
The cost-effectiveness estimates for galcanezumab are within the acceptable range set by NICE, particularly for episodic migraine, where the ICER is towards the lower end of the £20,000 to £30,000 per QALY range. This indicates that galcanezumab provides a good value proposition for the Healthcare, especially after multiple preventive treatments have failed. This informs pricing and reimbursement risk and pharmaceutical reimbursement forecasting.
Quality of life
The evidence suggests that galcanezumab improves health-related quality of life, as indicated by higher utility values compared to placebo. The use of differential utility values demonstrates that galcanezumab not only reduces the frequency of migraine attacks but also improves the burden of migraine between attacks, contributing positively to overall patient well-being. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Supporting Domains
Safety and Adverse Effects
Galcanezumab has a very good safety profile, with mostly mild to moderate adverse events reported. Serious adverse events are rare, and the overall tolerability is high, making it a favorable option compared to existing treatments that may have more significant side effects. This profile reduces payer uncertainty and supports access risk forecasting.
Comparator Selection
The clinical evidence for galcanezumab was compared against appropriate standards of care, including placebo for episodic migraine and botulinum toxin type A for chronic migraine. The committee concluded that these comparators are relevant and reflect the treatment landscape accurately. This aligns with HTA comparator analysis and strengthens the market access submission.
Patient Population and Subgroups
The trials included a representative population of patients who had failed multiple prior treatments, which aligns with the intended use of galcanezumab in clinical practice. The focus on patients with chronic and episodic migraine who have not responded to at least three preventive treatments ensures that the evidence is applicable to the target population. This enhances reimbursement likelihood rating and payer relevance.
Care Pathway Integration
Galcanezumab can be integrated into existing care pathways with minor adjustments, such as training for self-administration. The treatment is designed to be self-administered, which aligns well with current practices and reduces the need for extensive changes in healthcare delivery. This supports budget impact analysis and facilitates market access feasibility.
Resource Use and Cost Implications
The budget impact of galcanezumab is manageable, and while there are additional monitoring costs, the overall resource use is justified by the clinical benefits provided. The committee acknowledged that the treatment could lead to cost savings in the long term by reducing the burden of migraine on healthcare resources. This supports pricing model stress-testing and payer evidence expectations.
Evidence Quality and Robustness
The evidence base for galcanezumab is supported by multiple randomized controlled trials, which provide a strong foundation for its clinical effectiveness. While there are some uncertainties regarding long-term effectiveness, the overall quality of evidence is robust and reliable. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Uncertainty, Sensitivity, and Broader Impacts
There are some uncertainties regarding the long-term effectiveness of galcanezumab, particularly in extrapolating results beyond the trial periods. The committee noted these uncertainties but considered them manageable within the context of the treatment’s benefits and the high unmet need in the patient population. These factors elevate access risk forecasting within HTA evaluation frameworks.
